Schizophrenia and the gut–brain axis
Abstract
Several risk factors for the development of schizophrenia can be linked through a common pathway in the intestinal tract. It is now increasingly recognized that bidirectional communication exists between the brain and the gut that uses neural, hormonal, and immunological routes. An increased incidence of gastrointestinal (GI) barrier dysfunction, food antigen sensitivity, inflammation, and the metabolic syndrome is seen in schizophrenia. These findings may be influenced by the composition of the gut microbiota. A significant subgroup of patients may benefit from the initiation of a gluten and casein-free diet. Antimicrobials and probiotics have therapeutic potential for reducing the metabolic dysfunction and immune dysregulation seen in patients with schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The gut microbiota may confer beneficial effects on schizophrenia by regulating the expression of neurotrophic factor receptors and the levels of inflammatory factors and chemokines, thereby alleviating metabolic dysfunction.
“Notably, the gut microbiota may confer beneficial effects on SZ by regulating the expression of neurotrophic factor receptors and the levels of inflammatory factors and chemokines, thereby alleviating metabolic dysfunction and providing a new direction for obtaining beneficial effects in patients with SZ [20,21].”
From Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials (2025) · cites this paper as [20]
The citation lists haven’t been fetched yet
References 102 · Cited by 151
- Authors
- Nemani, K., Hosseini Ghomi, R., McCormick, B., & Fan, X.
- Affiliations
- NYU Langone Health (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Nemani, Katlyn
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 56
- Pages
- 155-160
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2082818899
- Cited by
- 151
- References
- 102
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 18 · 2023: 11 · 2022: 15 · 2021: 17 · 2020: 19 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 14 · 2015: 10
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- schizophrenia, gut-brain axis, gut microbiota, inflammation, metabolic syndrome, gluten-free diet, casein-free diet, probiotics, antimicrobial agents, immune dysregulation
- MeSH terms
- Anti-Infective Agents, Brain, Humans, Schizophrenia, Gastrointestinal Tract, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review